Tags

Type your tag names separated by a space and hit enter

Metabolic response to selenium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.
Clin Endocrinol (Oxf) 2015; 82(6):885-91CE

Abstract

OBJECTIVE

We are aware of no study examining the effects of selenium supplementation on metabolic profiles of patients with polycystic ovary syndrome (PCOS). This study was conducted to evaluate the effects of selenium supplementation on glucose homeostasis parameters and lipid concentrations in women with PCOS.

DESIGN, PATIENTS AND MEASUREMENTS

This randomized, double-blind, placebo-controlled trial was conducted among 70 women diagnosed with PCOS and aged 18-40 years old. Participants were randomly divided into two groups to receive 200 μg per day selenium supplements (N = 35) or placebo (N = 35) for 8 weeks. Fasting blood samples were taken at baseline and after 8 weeks intervention to quantify glucose, insulin and lipid concentrations.

RESULTS

After 8 weeks of intervention, subjects who received selenium supplements had significantly decreased serum insulin levels (-29·83 ± 47·29 vs +9·07 ± 77·12 pmol/l, P = 0·013), homeostasis model of assessment-insulin resistance (HOMA-IR) (-1·15 ± 1·81 vs +0·42 ± 3·09, P = 0·011), homeostatic model assessment-beta-cell function (HOMA-B) (-19·06 ± 30·95 vs +4·55 ± 47·99, P = 0·017) and increased quantitative insulin sensitivity check index (QUICKI) (+0·03 ± 0·04 vs +0·0009 ± 0·05, P = 0·032) compared with placebo. In addition, supplementation with selenium resulted in a significant reduction in serum triglycerides (-0·14 ± 0·55 vs +0·11 ± 0·30 mmol/l, P = 0·025) and VLDL-C concentrations (-0·03 ± 0·11 vs +0·02 ± 0·06 mmol/l, P = 0·025) compared with placebo.

CONCLUSIONS

In conclusion, 200 microgram per day selenium supplementation for 8 weeks among PCOS women had beneficial effects on insulin metabolism parameters, triglycerides and VLDL-C levels; however, it did not affect FPG and other lipid profiles.

Authors+Show Affiliations

Department of Gynecology and Obstetrics, School of Medicine, Arak University of Medical Sciences, Arak, I.R. Iran.Department of Gynecology and Obstetrics, School of Medicine, Ardabil University of Medical Sciences, Ardabil, I.R. Iran.Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, I.R. Iran.Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, I.R. Iran.Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, I.R. Iran.Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, I.R. Iran.

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25510442

Citation

Jamilian, Mehri, et al. "Metabolic Response to Selenium Supplementation in Women With Polycystic Ovary Syndrome: a Randomized, Double-blind, Placebo-controlled Trial." Clinical Endocrinology, vol. 82, no. 6, 2015, pp. 885-91.
Jamilian M, Razavi M, Fakhrie Kashan Z, et al. Metabolic response to selenium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clin Endocrinol (Oxf). 2015;82(6):885-91.
Jamilian, M., Razavi, M., Fakhrie Kashan, Z., Ghandi, Y., Bagherian, T., & Asemi, Z. (2015). Metabolic response to selenium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. Clinical Endocrinology, 82(6), pp. 885-91. doi:10.1111/cen.12699.
Jamilian M, et al. Metabolic Response to Selenium Supplementation in Women With Polycystic Ovary Syndrome: a Randomized, Double-blind, Placebo-controlled Trial. Clin Endocrinol (Oxf). 2015;82(6):885-91. PubMed PMID: 25510442.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Metabolic response to selenium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. AU - Jamilian,Mehri, AU - Razavi,Maryamalsadat, AU - Fakhrie Kashan,Zohreh, AU - Ghandi,Yasser, AU - Bagherian,Tayebeh, AU - Asemi,Zatollah, Y1 - 2015/01/26/ PY - 2014/11/11/received PY - 2014/12/03/revised PY - 2014/12/05/revised PY - 2014/12/07/accepted PY - 2014/12/17/entrez PY - 2014/12/17/pubmed PY - 2016/3/5/medline SP - 885 EP - 91 JF - Clinical endocrinology JO - Clin. Endocrinol. (Oxf) VL - 82 IS - 6 N2 - OBJECTIVE: We are aware of no study examining the effects of selenium supplementation on metabolic profiles of patients with polycystic ovary syndrome (PCOS). This study was conducted to evaluate the effects of selenium supplementation on glucose homeostasis parameters and lipid concentrations in women with PCOS. DESIGN, PATIENTS AND MEASUREMENTS: This randomized, double-blind, placebo-controlled trial was conducted among 70 women diagnosed with PCOS and aged 18-40 years old. Participants were randomly divided into two groups to receive 200 μg per day selenium supplements (N = 35) or placebo (N = 35) for 8 weeks. Fasting blood samples were taken at baseline and after 8 weeks intervention to quantify glucose, insulin and lipid concentrations. RESULTS: After 8 weeks of intervention, subjects who received selenium supplements had significantly decreased serum insulin levels (-29·83 ± 47·29 vs +9·07 ± 77·12 pmol/l, P = 0·013), homeostasis model of assessment-insulin resistance (HOMA-IR) (-1·15 ± 1·81 vs +0·42 ± 3·09, P = 0·011), homeostatic model assessment-beta-cell function (HOMA-B) (-19·06 ± 30·95 vs +4·55 ± 47·99, P = 0·017) and increased quantitative insulin sensitivity check index (QUICKI) (+0·03 ± 0·04 vs +0·0009 ± 0·05, P = 0·032) compared with placebo. In addition, supplementation with selenium resulted in a significant reduction in serum triglycerides (-0·14 ± 0·55 vs +0·11 ± 0·30 mmol/l, P = 0·025) and VLDL-C concentrations (-0·03 ± 0·11 vs +0·02 ± 0·06 mmol/l, P = 0·025) compared with placebo. CONCLUSIONS: In conclusion, 200 microgram per day selenium supplementation for 8 weeks among PCOS women had beneficial effects on insulin metabolism parameters, triglycerides and VLDL-C levels; however, it did not affect FPG and other lipid profiles. SN - 1365-2265 UR - https://www.unboundmedicine.com/medline/citation/25510442/Metabolic_response_to_selenium_supplementation_in_women_with_polycystic_ovary_syndrome:_a_randomized_double_blind_placebo_controlled_trial_ L2 - https://doi.org/10.1111/cen.12699 DB - PRIME DP - Unbound Medicine ER -